RhoA Promotes Synovial Proliferation and Bone Erosion in Rheumatoid Arthritis through Wnt/PCP Pathway by Ning Chen, Chao-Yue Diao, Xin Huang, Wei-Xing Tan, Ya-Bing Chen, Xin-Yu Qian, Jie Gao, Dong-Bao Zhao

“…These effects in RA-FLSs and osteoclasts were all regulated by RhoA/Rho-associated protein kinase 2 (ROCK2) and might interact with Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways.…”
Get full text

Ekspresi Protein Sitoplasmik SOCs2 pada Adenokarsinoma Kolorektal: Studi Imunohistokimia by Nita Afriani Azmal, Shinta Ayu Intan, Tofrizal Tofrizal

“…They increase signaling pathways into cells via the Janus kinase pathway (JAK) - signal transducer and activator of transcription (STAT) -suppressor of cytokine signaling (SOCs) JAK-STAT. …”
Get full text

BAY 11-7082 Is a Broad-Spectrum Inhibitor with Anti-Inflammatory Activity against Multiple Targets by Jaehwi Lee, Man Hee Rhee, Eunji Kim, Jae Youl Cho

“…In addition, BAY also suppressed the translocation and activation of activator protein-1, interferon regulatory factor-3, and signal transducer and activator of transcription-1 by inhibiting the phosphorylation or activation of extracellular signal-related kinase, p38, TANK-binding protein, and Janus kinase-2. These data strongly suggest that BAY is an inhibitor with multiple targets and could serve as a lead compound in developing strong anti-inflammatory drugs with multiple targets in inflammatory responses.…”
Get full text

Epigenetic regulation of the inflammatory response in stroke by Jingyi Liang, Fei Yang, Zixiao Li, Qian Li

“…In this review, we summarize current findings on the epigenetic regulation of the inflammatory response in stroke, focusing on key signaling pathways including nuclear factor-kappa B, Janus kinase/signal transducer and activator of transcription, and mitogen-activated protein kinase as well as inflammasome activation. …”
Get full text

A Case of Severe Multisystem Inflammatory Syndrome in Children (MIS-C) Treated with Multiple Biologics by Beenish Zulfiqar, Hira Imran, Kathleen Collins

“…He was treated successfully with immunomodulating medicines including intravenous immune globulin (IVIG), steroids, interleukin-6 inhibitor, tumor necrosis factor-a inhibitor, interleukin-1 inhibitor, and Janus kinase inhibitor.…”
Get full text

Efficacy And Safety Of Low Dose Tofacitinib As Induction Therapy In Moderate To Severe Ulcerative Colitis: A Pilot Study by Sadia Ahmed, Muhammad Umar, Muhammad Kamran, Misbah Noureen, Iqra Ashraf, Javeria Khan

“…Tofacitinib, an orally administered micromolecule, blocks the Janus kinase (JAK) signal transducer pathway, thereby reducing mucosal inflammation. …”
Get full text

Sarcoidosis: molecular mechanisms and therapeutic strategies by Danfeng Xu, Xiaohua Tao, Yibin Fan, Yan Teng

“…Promising therapeutic agents encompass inhibitors of cytokines, like those targeting tumor necrosis factor (TNF)-α, as well as inhibitors of signaling pathways, such as Janus kinase (JAK) inhibitors, which exhibit favorable prospects for application. …”
Get full text

Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis by K. Juczynska, A. Wozniacka, E. Waszczykowska, M. Danilewicz, M. Wagrowska-Danilewicz, J. Wieczfinska, R. Pawliczak, A. Zebrowska

“…A family of eleven proteins comprises the Janus kinases (JAK) and signal transducers and activators of transcription (STAT) signaling pathway, which enables transduction of signal from cytokine receptor to the nucleus and activation of transcription of target genes. …”
Get full text

Evolving trends in the prevalence and treatment of ankylosing spondylitis in Korea from 2010 to 2023: a population-based study by Yu-Seon Jung, Soo-Kyung Cho, Se Rim Choi, Sun-Young Jung, Yoon-Kyoung Sung

“…The introduction of interleukin-17 and Janus kinase (JAK) inhibitors, particularly as second- and third-line therapies, marked a significant development. …”
Get full text

Effects of Microbes on Insect Host Physiology and Behavior Mediated by the Host Immune System by Shan Zhang, Zhengyan Wang, Qiong Luo, Lizhen Zhou, Xin Du, Yonglin Ren

“…Toll, immune deficiency, and Janus kinase/signal transducers and activators of transcription are the main signaling pathways regulating insect humoral immunity. …”
Get full text

Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes... by Yuya Fujita, Masao Nawata, Atsushi Nagayasu, Kazuki Someya, Kazuyoshi Saito, Yoshiya Tanaka

“…Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. …”
Get full text

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump by Eamon Shamil, David Cunningham, Billy L. K. Wong, Piyush Jani

“…It was hypothesized that use of Ruxolitinib through its selective inhibition of Janus-activated kinases 1 and 2 resulted in immunosuppression and miliary tuberculosis in this patient. …”
Get full text

Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain by Han-Chung Lee, Kai-Leng Tan, Pike-See Cheah, King-Hwa Ling

“…However, the mechanism(s) and consequences of this slight neurogenic-to-gliogenic shift in DS brain are still poorly understood. To date, Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling has been proposed to be crucial in various developmental pathways, especially in promoting astrogliogenesis. …”
Get full text

Investigation of genes expression of the JAK/STAT signalling pathway and AMPs in the presence of Borrelia spirochetes in Ixodes ricinus by Magdalena Szczotko, Sandra Antunes, Ana Domingos, Małgorzata Dmitryjuk

“…Ticks have a basic innate immune system and protect themselves from infection through innate immune responses involving pathways such as Janus kinase (JAK) or the signalling transducer activator of transcription (STAT). …”
Get full text

IL-34 aggravates myocardial ischemia-reperfusion injury by upregulating the HMGB1-IL-17A-IL-6 axis through the JAK signaling pathway. by Ruisong Ma, Xiaochun Hu, Wenwen Fu, Xiaorong Hu

“…We also observed increased serum cardiac enzymes and a larger myocardial injury area. Treatment with a Janus kinase (JAK) pathway inhibitor, however, partially reduced the expression of these proteins and attenuated myocardial injury. …”
Get full text

Oral colon-targeted responsive chitosan/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy by Chunfei Wu, Chuanlin Bi, Geun-soo Kim, Zizhen Yang, Shuao Li, Tong Dai, Xiaoyu Wu, Jiaojiao Tan, Ningning He, Shangyong Li

“…Abstract Tofacitinib (Tof), a commercially available pan-Janus kinases inhibitor, is approved for the treatment of moderate to severe ulcerative colitis. …”
Get full text

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain by María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, Rudi Subirá

“…Identification of the Janus Kinase (JAK) gene mutations inaugurated a new era in the targeted therapy of myeloproliferative diseases. …”
Get full text

The Stability-Indicating Ultra High-Performance Liquid Chromatography with Diode Array Detector and Tandem Mass Spectrometry Method Applied for the Forced Degradation Study of Ritl... by Jelena Kovačić, Daniela Amidžić Klarić, Nikša Turk, Željko Krznarić, Emma Riordan, Ana Mornar

“…Background/Objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn’s disease. …”
Get full text

Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

“…Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). …”
Get full text

Natural products targeting ubiquitination to combat kidney fibrosis by Lianhua Li, Xinhui Huang, Yao Chen, Jibin Liu, Yuhang Qiao, Wenyu Fan, Peiqing Zhang, Xiaoming Yan, Ming Chen

“…Main body of the abstract Recent studies have shown that ubiquitination and deubiquitination represent promising intervention targets against renal fibrosis, with numerous natural products intervening in renal fibrosis by regulating the processes of ubiquitination and signal pathways such as transforming growth factor-β1/Smads (TGF-β1/Smads), Wnt/β-catenin, Janus kinase/signal transducer and activator of transcription/suppressor of cytokine signaling (JAK/STAT/SCOS), and nuclear factor erythroid-derived 2-like 2 (Nrf2), and then link. …”
Get full text